Psilocybin May Prevent Nerve Damage from Chemotherapy, Preliminary Study Finds

**New Human Trials Commence for Psilocybin’s Potential in Combatting Chemotherapy-Related Nerve Damage**

Exciting developments are underway in the realm of cancer treatment, with human trials set to commence this month examining the effects of psilocybin, commonly referred to as magic mushrooms. Recent research has indicated that this naturally occurring compound may play a role in preventing nerve damage associated with chemotherapy, a common and often debilitating side effect for cancer patients.

A study published on 3rd September in the journal *Science* highlighted the promising results from animal trials where psilocybin demonstrated capabilities of preventing peripheral neuropathy in mice. This condition, which is characterised by nerve damage outside the brain and spinal cord, can lead to significant discomfort and disability, presenting a serious challenge for those undergoing cancer treatment.

Specifically, the researchers found that administering two doses of psilocybin in pill form to the mice before chemotherapy protected them from “pain hypersensitivity caused by neurotoxic chemotherapies”. Remarkably, this protective effect persisted throughout eight months and across six rounds of chemotherapy without adversely affecting tumour growth or the immune response. This finding suggests that psilocybin could offer significant therapeutic value for a diverse group of cancer patients experiencing nerve damage.

Peripheral neuropathy is recognised as a common side effect of many chemotherapy regimes. According to insights provided by the Cleveland Clinic, it can result in symptoms such as numbness, difficulty in movement, and even a complete loss of reflexes. Such outcomes can drastically affect patients’ quality of life, with the condition often being irreversible, thus underlining the importance of finding effective preventative solutions.

While psilocybin has garnered attention in recent years largely for its applications in treating various mental health disorders, including depression and anxiety, this new focus on its physiological effects could usher in a new era for oncology care. At present, the legal landscape surrounding psychedelics remains complex, with their therapeutic use only sanctioned in states like Oregon and Colorado, while being classified as illegal federally.

The implications of the research are significant. Notably, the effectiveness of psilocybin does not appear to rely on its hallucinogenic properties, as both hallucinogenic and non-hallucinogenic forms produced similar protective results in the study. This aspect raises intriguing possibilities for the application of psilocybin in clinical settings without the psychological effects that typically accompany psychedelic therapies.

However, it remains uncertain whether psilocybin could be beneficial in treating or reversing existing cases of neuropathy. The upcoming human trials will specifically focus on patients diagnosed with breast, colorectal, and head and neck cancers, marking a critical step in translating these findings from animal studies into real-world applications.

In contrast to the two doses given to the mice, participants in the human trials will receive four doses of psilocybin—two prior to chemotherapy and two during treatment. Researchers aim to comprehensively evaluate the impact of psilocybin on patients’ quality of life, monitoring aspects such as sleep, mental health, pain, and overall functionality throughout the process.

As these trials get underway, the medical community will be watching closely to see if psilocybin can indeed provide a new method to enhance the comfort and well-being of those navigating the often harsh realities of chemotherapy. If successful, this could represent a significant advancement in managing the side effects of cancer treatment, sparking further interest in the therapeutic potential of psychedelics within medical science.